Bristol Myers Squibb vs Eli Lilly (BMY vs LLY)
Bristol Myers Squibb (BMY) vs Eli Lilly (LLY) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Bristol Myers Squibb (BMY) and Eli Lilly (LLY) compete in healthcare and pharma. Here are Bristol Myers Squibb and Eli Lilly side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bristol Myers Squibb or Eli Lilly.
Bristol Myers Squibb vs Eli Lilly: the figures
| Figure | Bristol Myers Squibb | Eli Lilly |
|---|---|---|
| Share price | $64.19 (November 4, 2026) | $1,417.99 (November 4, 2026) |
| Market cap | $131.2 billion | $1.26 trillion |
| P/E (TTM) | 14.2x | 46.0x |
| Forward P/E | 9.6x | 28.3x |
| Revenue growth (quarter) | +6.9% | +38.6% |
| Net margin (TTM) | 18.5% | 31.9% |
| Net debt / EBITDA | 1.8x | 1.0x |
| Dividend yield | 4.08% | 0.49% |
| Beta | 0.19 | 0.39 |
Bristol Myers Squibb and Eli Lilly figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Bristol Myers Squibb or Eli Lilly figure is not available, and we never estimate it.
3 key differences between Bristol Myers Squibb and Eli Lilly
- Valuation: Eli Lilly trades at 46.0x its annual earnings and Bristol Myers Squibb at 14.2x; the market pays more for each dollar of Eli Lilly profit, usually because it expects more growth.
- Growth: Eli Lilly grew sales +38.6% year on year in its latest quarter, against +6.9% for Bristol Myers Squibb.
- Dividend: Bristol Myers Squibb yields 4.08% at today's price and Eli Lilly yields 0.49%.
Bristol Myers Squibb or Eli Lilly: which fits your profile
- If you want growth: Eli Lilly is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Bristol Myers Squibb pays the higher dividend relative to its price.
- If you prefer caution: Eli Lilly has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Bristol Myers Squibb trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Bristol Myers Squibb nor Eli Lilly wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Bristol Myers Squibb and Eli Lilly make money
Bristol Myers Squibb (BMY)
Bristol Myers Squibb sells prescription drugs in a single segment. Its biggest products are Eliquis, a blood thinner marketed with Pfizer, and Opdivo, a cancer immunotherapy, along with Revlimid, Pomalyst, Breyanzi, Camzyos and the schizophrenia drug Cobenfy. The United States generates most of its revenue. Full Bristol Myers Squibb analysis.
Eli Lilly (LLY)
Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. The United States is its biggest market. Full Eli Lilly analysis.
Frequently asked questions: Bristol Myers Squibb vs Eli Lilly
Is Bristol Myers Squibb or Eli Lilly the better stock?
Choosing between Bristol Myers Squibb and Eli Lilly depends on what you are looking for. Eli Lilly is growing faster right now, and Bristol Myers Squibb trades on the lower P/E. Fintols does not tell you whether to buy Bristol Myers Squibb or Eli Lilly: it shows you the differences so you can decide.
Which pays a higher dividend, Bristol Myers Squibb or Eli Lilly?
As of November 4, 2026, Bristol Myers Squibb yields 4.08% and Eli Lilly yields 0.49%. Also check how much of their profit Bristol Myers Squibb and Eli Lilly pay out: if it is more than they earn, it cannot last.
Which is more expensive, Bristol Myers Squibb or Eli Lilly?
On P/E, Eli Lilly (46.0x) is more expensive than Bristol Myers Squibb (14.2x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Can I own both Bristol Myers Squibb and Eli Lilly?
Yes. Many people spread their money across several companies, such as Bristol Myers Squibb and Eli Lilly, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Bristol Myers Squibb or Eli Lilly.
More comparisons with Bristol Myers Squibb or Eli Lilly
- Bristol Myers Squibb vs CVS Health
- Bristol Myers Squibb vs Danaher
- Bristol Myers Squibb vs Gilead
- AbbVie vs Eli Lilly
More companies like Bristol Myers Squibb and Eli Lilly: healthcare and pharma stocks. Educational content about Bristol Myers Squibb and Eli Lilly, not investment advice.